Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

NCT06727058 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

276

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza Immunization

Interventions

BIOLOGICAL: Pandemic flu H5 mRNA vaccine
OTHER: Placebo

Sponsor

Sanofi Pasteur, a Sanofi Company